Current Developments in HIV Chemotherapy

No abstract is available for this paper.

• Publication year

  2006

• Venue

  ChemMedChem

• Publication date

  2006-01-16

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/cmdc.200500026PMID 16892329
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human retroviruses

  2014cited by this paper
• Synthesis and biological evaluation of geminal disulfones as HIV-1 integrase inhibitors.

  2005cited by this paper
• New approaches toward anti-HIV chemotherapy.

  2005cited by this paper
• New approaches toward anti-HIV chemotherapy.

  2005cited by this paper
• A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.

  2004cited by this paper
• New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections.

  2004cited by this paper
• New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections.

  2004cited by this paper
• Blocking viral entry: a complementary strategy for HIV therapy

  2004cited by this paper
• Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques

  2004cited by this paper
• Antiretroviral nucleoside and nucleotide analogues and mitochondria.

  2004cited by this paper
• Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.

  2004cited by this paper
• HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications.

  2004cited by this paper
• Non‐Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and Future

  2004cited by this paper
• Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.

  2004cited by this paper
• A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120.

  2004cited by this paper
• Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase.

  2004cited by this paper
• Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins.

  2004cited by this paper
• Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.

  2004cited by this paper
• A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

  2003cited by this paper
• Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125.

  2003cited by this paper
• HIV-1 Resistance Profile of the Novel Nucleoside Reverse Transcriptase Inhibitor β-D-2′,3′-Dideoxy-2′,3′-Didehydro-5-Fluorocytidine (Reverset™)

  2003cited by this paper
• Dimerization inhibitors of HIV-1 protease based on a bicyclic guanidinium subunit.

  2003cited by this paper
• Capravirine: Anti-HIV agent prop inn reverse transcriptase inhibitor

  2003cited by this paper
• Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update.

  2003cited by this paper
• Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells.

  2003cited by this paper
• Extended Treatment With Tenofovir Disoproxil Fumarate in Treatment‐Experienced HIV‐1‐Infected Patients: Genotypic, Phenotypic, and Rebound Analyses

  2003cited by this paper
• Dioxolane Guanosine, the Active Form of the Prodrug Diaminopurine Dioxolane, Is a Potent Inhibitor of Drug‐Resistant HIV‐1 Isolates From Patients for Whom Standard Nucleoside Therapy Fails

  2002cited by this paper
• Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance

  2002cited by this paper
• Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors.

  2002cited by this paper
• HIV entry inhibitors in clinical development.

  2002cited by this paper
• From Phosphate to Bis(methylene) Sulfone: Non-Ionic Backbone Linkers in DNA

  2002cited by this paper
• New developments in anti-HIV chemotherapy.

  2002cited by this paper
• Inhibition of Human Immunodeficiency Virus Type 1 Integration by Diketo Derivatives

  2002cited by this paper
• HIV Integrase, a Brief Overview from Chemistry to Therapeutics*

  2001cited by this paper
• HIV chemotherapy

  2001cited by this paper
• Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine.

  2001cited by this paper
• Structure of a two‐domain fragment of HIV‐1 integrase: implications for domain organization in the intact protein

  2001cited by this paper
• Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection.

  2001cited by this paper
• Origin pairing (‘handcuffing’) as a mode of negative control of P1 plasmid copy number

  2001cited by this paper
• Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.

  2001cited by this paper
• Protease Inhibitors in AIDS Therapy

  2001cited by this paper
• HIV chemotherapy : AIDS

  2001cited by this paper
• New developments in anti-HIV chemotherapy

  2001cited by this paper
• Mechanism of Action of 1-β-d-2,6-Diaminopurine Dioxolane, a Prodrug of the Human Immunodeficiency Virus Type 1 Inhibitor 1-β-d-Dioxolane Guanosine

  2001cited by this paper
• A novel reagent for the synthesis of geminal di-sulfones

  2001cited by this paper
• Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population

  2000cited by this paper
• HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase.

  2000cited by this paper
• Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy

  2000cited by this paper
• Binding of the Second Generation Non-nucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding*

  2000cited by this paper
• Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors.

  2000cited by this paper
• 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells.

  2000cited by this paper
• Retroviral integrase inhibitors year 2000: update and perspectives.

  2000cited by this paper
• Structural and biochemical studies of retroviral proteases.

  2000cited by this paper
• Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options.

  2000cited by this paper
• Recognition and Inhibition of HIV Integrase by Novel Dinucleotides

  2000cited by this paper
• Interpretation of Resistance Assay Results

  2000cited by this paper
• Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

  2000cited by this paper
• Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.

  2000cited by this paper
• Transmission and Prevalence of HIV Resistance among Treatment-Naive Subjects

  2000cited by this paper
• Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.

  1999cited by this paper
• DNA Polymerases: Structural Diversity and Common Mechanisms*

  1999cited by this paper
• Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design.

  1999cited by this paper
• Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.

  1999cited by this paper
• Chicoric acid analogues as HIV-1 integrase inhibitors.

  1999cited by this paper
• Transmission of antiretroviral-drug-resistant HIV-1 variants.

  1999cited by this paper
• Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium.

  1998cited by this paper
• A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

  1998cited by this paper
• Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

  1998cited by this paper
• HIV entry and its inhibition.

  1998cited by this paper
• Severe premature coronary artery disease with protease inhibitors.

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.

  1998cited by this paper
• Sequence specificity of viral end DNA binding by HIV‐1 integrase reveals critical regions for protein–DNA interaction

  1998cited by this paper
• Structural biology: A mechanism for all polymerases

  1998cited by this paper
• Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

  1997cited by this paper
• Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein.

  1997cited by this paper
• Solution structure of the N-terminal zinc binding domain of HIV-1 integrase

  1997cited by this paper
• Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors

  1997cited by this paper
• Atomic structure of the ectodomain from HIV-1 gp41

  1997cited by this paper
• Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

  1997cited by this paper
• 2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones.

  1996cited by this paper
• Cell protein cross-linking by erbstatin and related compounds.

  1996cited by this paper
• Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

  1996cited by this paper
• Retroviral Integrase, Putting the Pieces Together*

  1996cited by this paper
• Inhibitors of HIV-1 replication that inhibit HIV integrase

  1996cited by this paper
• A Soluble Active Mutant of HIV-1 Integrase

  1996cited by this paper
• Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase.

  1996cited by this paper
• Inhibition of human immunodeficiency virus integrase by bis-catechols

  1995cited by this paper
• Hydroxylated aromatic inhibitors of HIV-1 integrase.

  1995cited by this paper
• Solution structure of the DNA binding domain of HIV-1 integrase.

  1995cited by this paper
• Tyrosine kinase inhibition: an approach to drug development.

  1995cited by this paper
• L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.

  1994cited by this paper
• Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds.

  1994cited by this paper
• Design, synthesis, and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus reproduction.

  1994cited by this paper
• Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents

  1993cited by this paper
• Inhibitors of human immunodeficiency virus integrase.

  1993cited by this paper
• Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogs, and polymer fractions.

  1992cited by this paper
• Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro

  1992cited by this paper
• Retroviral integrase functions as a multimer and can turn over catalytically.

  1992cited by this paper
• Building blocks for oligonucleotide analogues with dimethylene sulfide, sulfoxide, and sulfone groups replacing phosphodiester linkages

  1991cited by this paper

• Synthesis and Resolution of 4'-Substituted Nucleosides with Potential Antiviral and Antisense Strategies.

  2025cites this paper
• Antiviral activity and active components of the leaves from Sabia parviflora Wall. ex Roxb

  2023cites this paper
• Supramolecular Architecture through Self-Organization of Janus-Faced Homoazanucleosides.

  2020cites this paper
• Anti-HIV Drug Discovery, Development and Synthesis of Delavirdine: Review Article

  2019cites this paper
• Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase

  2018cites this paper
• Synthesis of 4'-Thionucleosides as Antitumor and Antiviral Agents.

  2018cites this paper
• Glycosylation reactions mediated by hypervalent iodine: application to the synthesis of nucleosides and carbohydrates

  2018cites this paper
• Progress in HIV-1 Integrase Inhibitors: A Review of their Chemical Structure Diversity

  2016cites this paper
• Construction of an Isonucleoside on a 2,6-Dioxobicyclo[3.2.0]-heptane Skeleton

  2015cites this paper
• Synthesis and Biological Evaluation of 2-Thioxopyrimidin-4(1H)-one Derivatives as Potential Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors

  2014cites this paper
• In silico identification of Novel HIV- Protease inhibitors (PIs) using ZINC drug Database

  2014cites this paper
• Inhibiting the HIV Integration Process: Past, Present, and the Future

  2014cites this paper
• Evolução da resistência in vivo aos inibidores da transcriptase reversa em mães multíparas infectadas pelo vírus da Imunodeficiênca Humana tipo 1 que cumpriram regimes terapêuticos para prevenção da transmissão do vírus aos seus filhos

  2013cites this paper
• Inhibiting the HIV Integration Process: Past, Present, and the Future

  2013cites this paper
• Designing a Soluble Near Full-length HIV-1 gp41 Trimer*

  2012cites this paper
• Synthesis and biological evaluation of 3'-C-ethynyl and 3'-C-(1,4-disubstituted-1,2,3-triazolo) double-headed pyranonucleosides.

  2012cites this paper
• Stereocontrolled synthesis of 4'-C-cyano and 4'-C-cyano-4'-deoxy pyrimidine pyranonucleosides as potential chemotherapeutic agents.

  2012cites this paper
• A Versatile and Practical Synthesis toward the Development of Novel HIV‐1 Integrase Inhibitors

  2011cites this paper
• Synthesis and biological evaluation of unsaturated keto and exomethylene D-arabinopyranonucleoside analogs: novel 5-fluorouracil analogs that target thymidylate synthase.

  2011cites this paper
• Synthesis of 5-thiodidehydropyranylcytosine derivatives as potential anti-HIV agents.

  2011cites this paper
• Gene Regulatable Lentiviral Vector System

  2011cites this paper
• Synthesis, gp120 binding and anti-HIV activity of fatty acid esters of 1,1-linked disaccharides.

  2011cites this paper
• Diversidade genética e resistência aos anti-retrovirais inibidores enzimáticos de vírus da imunodeficiência humana tipo 1 (HIV-1) de uma população de toxicodependentes por via endovenosa da Grande Lisboa

  2010cites this paper
• Research Article: Synthesis, Biological Evaluation and Molecular Modeling Studies of N‐aryl‐2‐arylthioacetamides as Non‐nucleoside HIV‐1 Reverse Transcriptase Inhibitors

  2010cites this paper
• Design and synthesis of isonucleosides constructed on a 2-oxa-6-thiabicyclo[3.2.0]heptane scaffold.

  2010cites this paper
• Synthesis and anti-HIV activity of 2'-deoxy-2'-fluoro-4'-C-ethynyl nucleoside analogs.

  2010cites this paper
• Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?

  2010cites this paper
• Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors.

  2009cites this paper
• Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance.

  2009cites this paper
• A cascade approach to cyclic aminonitrones: reaction discovery, mechanism, and scope.

  2009cites this paper
• Synthesis and anti-HIV activity of conformationally restricted bicyclic hexahydroisobenzofuran nucleoside analogs.

  2009cites this paper
• Maintaining the silence: reflections on long-term RNAi

  2008cites this paper
• Drug discovery and development with plant-derived compounds.

  2008cites this paper
• Vinyl sulfones.

  2008cites this paper
• Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors.

  2008cites this paper
• C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors.

  2008cites this paper
• Recent advances in antiviral activity of benzo/heterothiadiazine dioxide derivatives.

  2008cites this paper
• Human Immunodeficiency Viruses: Antiretroviral Agents

  2008cites this paper
• Hydrolysis of thioesters in an ion trap.

  2008cites this paper
• Design and synthesis of a novel ring-expanded 4′-thio-apio-nucleoside derivatives

  2007cites this paper
• Toward novel HIV-1 integrase binding inhibitors: molecular modeling, synthesis, and biological studies.

  2007cites this paper
• Slow‐, Tight‐Binding HIV‐1 Reverse Transcriptase Non‐Nucleoside Inhibitors Highly Active against Drug‐Resistant Mutants

  2007cites this paper
• Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants.

  2007cites this paper
• Molecular mechanisms of HIV integration and therapeutic intervention

  2007cites this paper
• HIV-1 integrase: from biology to chemotherapeutics.

  2007influential citation
• Cu2(OTf)2-catalyzed and microwave-controlled preparation of tetrazoles from nitriles and organic azides under mild, safe conditions.

  2007cites this paper
• Theoretical study on the HIV-1 integrase inhibitor 1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)-propenone (5CITEP)

  2007cites this paper
• Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex

  2007cites this paper
• Rational optimization of the binding affinity of CD4 targeting peptidomimetics with potential anti HIV activity.

  2007cites this paper
• Virus animali come modello nello studio in vitro dell'attivitàdi molecole antivirali: applicazioni future in medicinaveterinaria e nei confronti di virus filogeneticamente correlatiresponsabili di patologie umane.

  2007cites this paper
• Pyridin‐2(1H)‐ones: A Promising Class of HIV‐1 Non‐nucleoside Reverse Transcriptase Inhibitors

  2007cites this paper
• New synthesis of (+/-)-isonucleosides.

  2006cites this paper
• Correlation of Biological Activity with Active Site Binding Modes of Geminal Disulfone HIV‐1 Integrase Inhibitors

  2006cites this paper
• Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.

  2006cites this paper
• Strategies for identification of HIV-1 integrase inhibitors

  2006cites this paper
• Arylthiopyrrole (AThP) Derivatives as Non‐Nucleoside HIV‐1 Reverse Transcriptase Inhibitors: Synthesis, Structure–Activity Relationships, and Docking Studies (Part 2)

  2006cites this paper